Tenaya Therapeutics, Inc.: share-based compensation expense
Share-based compensation expense for Tenaya Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Tenaya Therapeutics, Inc. financial histories
What this measure means
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
Exact concept: us-gaap:ShareBasedCompensation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 13,046,000 | USD | 2026-03-11 | 10-K · 0001193125-26-102252 |
| 2024-01-01 | 2024-12-31 | 16,501,000 | USD | 2026-03-11 | 10-K · 0001193125-26-102252 |
| 2023-01-01 | 2023-12-31 | 15,309,000 | USD | 2025-03-10 | 10-K · 0000950170-25-036329 |
| 2022-01-01 | 2022-12-31 | 11,467,000 | USD | 2024-03-18 | 10-K · 0000950170-24-032828 |
| 2021-01-01 | 2021-12-31 | 2,950,000 | USD | 2023-03-08 | 10-K · 0000950170-23-006725 |
| 2020-01-01 | 2020-12-31 | 741,000 | USD | 2022-03-23 | 10-K · 0000950170-22-004426 |
Related financial histories
- Tenaya Therapeutics, Inc.: total assets
- Tenaya Therapeutics, Inc.: total liabilities
- Tenaya Therapeutics, Inc.: stockholders equity
- Tenaya Therapeutics, Inc.: cash and cash equivalents
- Tenaya Therapeutics, Inc.: net income or loss
- Tenaya Therapeutics, Inc.: operating cash flow
- Tenaya Therapeutics, Inc.: capital expenditure payments
- Tenaya Therapeutics, Inc.: financing cash flow
- Tenaya Therapeutics, Inc.: investing cash flow
- Tenaya Therapeutics, Inc.: retained earnings or deficit
- Tenaya Therapeutics, Inc.: basic weighted-average shares
- Tenaya Therapeutics, Inc.: diluted weighted-average shares
- Tenaya Therapeutics, Inc.: basic earnings per share
- Tenaya Therapeutics, Inc.: diluted earnings per share
- Tenaya Therapeutics, Inc.: net property, plant and equipment
- Tenaya Therapeutics, Inc.: operating income or loss
- Tenaya Therapeutics, Inc.: current assets
- Tenaya Therapeutics, Inc.: current liabilities
- Tenaya Therapeutics, Inc.: current accounts payable
- Tenaya Therapeutics, Inc.: operating expenses
- Tenaya Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Tenaya Therapeutics, Inc. / CIK 0001858848
- Captured
- 2026-09-21T17:33:09.643Z
- SEC response SHA-256
8c0c2d88cb093609725b250d0cd55ebce41b67e41d3b2a73038b34021f7a1555
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001858848.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))